Health Care · Pharmaceutical Preparations

BHC Bausch Health Companies Inc SEC Filings & Insider Trading Activity 2026

company
CIK 88559078 filings

BHC at a glance

Bausch Health Companies Inc (BHC, SEC CIK 885590) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Bausch Health Companies Inc (BHC) shares worth $656.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Lenar Aimee J. on August 19, 2026 of 36,827 shares at $7.03 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$10.3B
+6.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$656.0M · +1 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New governance risk: Thomas Appio became Bausch + Lomb interim CEO October 12, 2026
  • Management bandwidth risk: Appio’s overlapping CEO roles may create competing demands
  • Conflict-of-interest risk: Appio also became Bausch + Lomb chairman in August 2026
  • Reputational risk: dual-company responsibilities may create actual or perceived conflicts

Management Discussion & Analysis

  • Revenue $2,941M, up 10% YoY from $2,681M, driven by pricing gains and acquisitions
  • Operating margin 33.4% vs 23.1% YoY, with operating income $983M vs $619M
  • Best segment: Salix revenue $831M, up 16%; worst growth: International revenue $299M, up 5%
  • Nine-month operating cash flow $1,714M vs $905M; ending cash $2,488M vs $1,340M
  • Near-term headwinds: Xifaxan negotiated pricing effective 2027, generic entry expected 2028, and ongoing tariff and regulatory risks

AI summary of the BHC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $2.94B, up 10%; Adjusted EBITDA $1.305B, up 32%, signaling strong operating leverage
  • GAAP EPS $1.15 versus $0.48; adjusted EPS $1.77 versus $1.16, a 53% increase

Item 2.02: Results of Operations and Financial Condition

  • Bausch Health announced third-quarter results for the quarter ended September 30, 2026
  • Press release includes financial information as of and for the quarter ended September 30, 2026
Filed Jul 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Bausch Health’s results for quarter ended June 30, 2026
  • Exhibit 99.1 contains operating results and other financial information for the quarter

Item EX-99.1: Item EX-99.1

  • Q2 revenue $2.85B, up 13% reported and 11% organic, indicating broad-based operating momentum
  • GAAP EPS $0.68 versus $0.40, while adjusted EPS rose 40% to $1.26
Filed Jul 1, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Michael Goettler resigning from Bausch Health’s Board effective June 30, 2026
  • Departure tied to his appointment as President and CEO of Knoa Pharma LLC

Item 7.01: Regulation FD Disclosure

  • Press release announces Mr. Goettler’s resignation, signaling a senior leadership transition
  • Investor focus: successor appointment, timing, and potential strategy or execution impact

AI summaries of BHC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BHC

Don't miss the next BHC filing

  • Alerts as it files. A push when BHC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BHC, by share count.
  • Ask anything. An AI agent that reads every BHC filing and answers with sources.

BHC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Paulson JohnASep 30, 2026$5.83
WECHSLER AMY BASep 30, 2026$5.83
LEUNG SANDRAASep 30, 2026$5.83
Lenar Aimee J.SellAug 19, 2026$7.03
Lenar Aimee J.FJul 17, 2026$4.83
Lenar Aimee J.FJul 15, 2026$4.89
LEE STEVEN HYOSIGFJul 14, 2026$4.75
Lee Frank D.SellMay 19, 2026$5.43

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$9.6B$10.3B
Operating Income-$1.5B$1.8B
Net Income-$592.0M-$46.0M$157.0M
Op. Margin-16.1%17.7%
Net Margin--0.5%1.5%
Balance Sheet
Total Assets$27.4B$26.5B$26.4B
Equity--$1.3B-$554.0M
ROE-3.6%-28.3%
Per Share
EPS$-1.62$-0.13$0.42
Cash Flow
Operating CF-$1.6B$1.4B
CapEx$215.0M$337.0M$397.0M

Source: XBRL data in Bausch Health Companies Inc (BHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BHC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BHC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$656.0M
Q2 202623$506.9M
Q1 202623$532.0M
Q4 202524$738.0M
Q3 202524$630.0M
Q2 202523$604.0M
Q1 202521$580.3M
Q4 202418$750.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BHC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 29, 2026Analysis
8-KOct 28, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Aug 20, 2026--
10-QJul 30, 2026-
8-KJul 29, 2026Analysis-
4Jul 20, 2026--
4Jul 17, 2026--
4Jul 15, 2026--
8-KJul 1, 2026Analysis-
4May 20, 2026-
8-KMay 19, 2026-
10-QApr 30, 2026-
8-KApr 29, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Mar 3, 2026--
8-KMar 2, 2026Analysis-
4Feb 27, 2026--
4Feb 27, 2026--
4Feb 27, 2026--
10-KFeb 19, 2026-
8-KFeb 18, 2026Analysis

Related Health Care companies

All Health Care →

BHC SEC filings: frequently asked questions

Which institutions hold BHC stock?

As of September 30, 2026, the largest Bausch Health Companies Inc (BHC) holders among the 13F filers tracked by SignalX were Paulson & Co ($427.1 million), Goldman Sachs Group ($45.2 million), Vanguard Capital Management LLC ($43.4 million), Two Sigma Investments ($43.2 million), D.E. Shaw & Co ($20.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BHC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Bausch Health Companies Inc (BHC) reported revenue of $10.3 billion (up 6.7% from FY2024) and net income of $157.0 million. Diluted EPS was $0.42. The figures come from the XBRL data in the 10-K.

What did BHC report in its latest 8-K?

Bausch Health Companies Inc (BHC) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $2.94B, up 10%; Adjusted EBITDA $1.305B, up 32%, signaling strong operating leverage.

What are the latest BHC SEC filings?

Bausch Health Companies Inc (BHC) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on October 2, 2026.

What is BHC's SEC CIK number?

Bausch Health Companies Inc (BHC)'s SEC Central Index Key (CIK) is 885590. EDGAR lists every BHC filing under that number.

Ask anything about BHC

The research agent reads BHC's filings, financials, insider trades and 13F holders, then answers with sources.